Publicaciones en colaboración con investigadores/as de National Cancer Institute (156)

2024

  1. Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma

    Cancer Epidemiology, Vol. 92

  2. PD-1H/VISTA mediates immune evasion in acute myeloid leukemia

    The Journal of clinical investigation, Vol. 134, Núm. 3

  3. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

    Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152

2023

  1. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways

    Cancer Discovery, Vol. 13, Núm. 11, pp. 2370-2393

  2. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  3. Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program

    Annals of Epidemiology, Vol. 77, pp. 1-12

  4. Evaluation of trefoil factor 3 as a non-invasive biomarker of gastric intestinal metaplasia and gastric cancer in a high-risk population

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 6, pp. 411-418

  5. Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics

    Clinical Cancer Research, Vol. 29, Núm. 12, pp. 2250-2265

  6. Global Cancer Surgery: pragmatic solutions to improve cancer surgery outcomes worldwide

    The Lancet Oncology, Vol. 24, Núm. 12, pp. e472-e518

  7. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

    Annals of Oncology, Vol. 34, Núm. 1, pp. 48-60

  8. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

    Nature Medicine, Vol. 29, Núm. 6, pp. 1370-1378

  9. Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia

    Seminars in Hematology

2022

  1. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

    The Lancet Oncology, Vol. 23, Núm. 8, pp. e374-e384

  2. Genomic profiling for clinical decision making in lymphoid neoplasms

    Blood

  3. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268

  4. Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR-Driven Lung Cancer

    Advanced Science, Vol. 9, Núm. 26

  5. The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations

    JCO global oncology, Vol. 8, pp. e2200123

  6. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Blood, Vol. 140, Núm. 11, pp. 1229-1253

2021

  1. Considerations for treatment duration in responders to immune checkpoint inhibitors

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

  2. Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy

    Cancer Letters, Vol. 499, pp. 279-289